Catalent (STU:0C8) Change In Receivables : €155 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Catalent Change In Receivables?

Catalent's change in receivables for the quarter that ended in Mar. 2024 was €-32 Mil. It means Catalent's Accounts Receivable increased by €32 Mil from Dec. 2023 to Mar. 2024 .

Catalent's change in receivables for the fiscal year that ended in Jun. 2023 was €49 Mil. It means Catalent's Accounts Receivable declined by €49 Mil from Jun. 2022 to Jun. 2023 .

Catalent's Accounts Receivable for the quarter that ended in Mar. 2024 was €805 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Catalent's Days Sales Outstanding for the three months ended in Mar. 2024 was 74.34.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Catalent's liquidation value for the three months ended in Mar. 2024 was €-4,660 Mil.

Catalent Change In Receivables Historical Data

The historical data trend for Catalent's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Change In Receivables Chart

Catalent Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-105.32

-134.09

-154.38

-69.06

48.92

Catalent Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-121.42	32.31	149.92	4.59	-32.20

Catalent Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €155 Mil.

Catalent (STU:0C8) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Catalent's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	805	/	988.08	*	91
=	74.34

2. In Ben Graham's calculation of liquidation value, Catalent's accounts receivable are only considered to be worth 75% of book value:

Catalent's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	149.04	-	5766.56	+	0.75 * 805	+	0.5 * 708.4
=	-4,660

Catalent Change In Receivables Related Terms

Thank you for viewing the detailed overview of Catalent's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent (STU:0C8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (STU:0C8) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CTLT:USA

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Catalent (STU:0C8) Headlines

No Headlines